Nanomedicine has made significant advances in clinical applications since the late-20th
century, in part due to its distinct advantages in biocompatibility, potency, and novel …

Background Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in
clear-cell renal-cell carcinoma in early-phase studies. Methods In a phase 3, multicenter …

Background The efficacy and safety of treatment with cabozantinib in combination with
nivolumab and ipilimumab in patients with previously untreated advanced renal-cell …

Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …

Background In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab
significantly improved progression-free survival and overall survival versus sunitinib in …

The COVID-19 pandemic has broadly impacted biomedical research and health care. Here
we discuss current challenges for the cancer research community as they apply to early …

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …

Background Renal cell carcinoma (RCC) is a heterogeneous disease comprising
histologically defined subtypes. For therapy selection, precise subtype identification and …

Summary Background Immune checkpoint inhibitors (ICIs) and vascular endothelial growth
factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced …

Introduction The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab
significantly improved efficacy versus sunitinib as first-line treatment for patients with …